Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Comprehensive Lung Health (CLUES)

6. november 2026 opdateret af: Ankit Bharat, Northwestern University

Comprehensive Lung Health Screening and Its Utility for Early Risk and Disease Stratification

Respiratory illnesses are a leading cause of morbidity and mortality worldwide, yet their prevalence in the general population remains poorly characterized. Computed tomography (CT) is the most effective diagnostic tool for identifying respiratory illnesses that cause changes to the lung parenchyma, such as pulmonary infections, fibrosis, and nodules. The diagnostic power of CT led the US Preventive Services Task Force (USPSTF) to issue lung cancer screening guidelines. In this prospective, observational cohort study, the study team will recruit 10,000 individuals aged 21 to 85 years, stratified into three cohorts: Cohort 1 (Medical Indication Group), Cohort 2 (Guideline-Based Screening Group), and Cohort 3 (Asymptomatic Research Low-Dose CT [LDCT] Group). The primary analysis will estimate the baseline cross-sectional prevalence of LDCT-detectable pulmonary findings in Cohort 3. Secondary analyses will compare baseline LDCT findings across all three cohorts and evaluate baseline associations between risk/exposure variables and CT findings. Exploratory follow-up analyses will use clinical data from the electronic health record (EHR), as available, for up to 5 years after the baseline/index CT. This study has the potential to transform health screening strategies, reduce disease burden, and improve health outcomes across diverse populations.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

10000

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Rekruttering
        • Northwestern Medicine
        • Ledende efterforsker:
          • Ankit Bharat, MD
        • Kontakt:
        • Underforsker:
          • Momen Wahidi, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

21 år til 85 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

All Cohorts:

•Adults 21 through 85 years of age.

Cohort 1:

•Clinical indication for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 activities are routine clinical care; research activity is secondary data use.

Cohort 2:

•Individuals who currently meet USPSTF criteria for LDCT lung cancer screening. Cohort 2 activities are routine clinical care; research activity is secondary data use.

Cohort 3:

  • Asymptomatic individuals who:
  • Do not have a clinical indication for chest CT
  • Do not meet current USPSTF criteria for LDCT lung cancer screening
  • Able to provide informed consent

Exclusion Criteria:

All Cohorts:

•Individuals below the age of 21 and above the age of 85.

Cohort 3:

  • Meets USPSTF guideline-based indications for LDCT lung cancer screening or has a clinical indication for chest CT.
  • Any chest CT within the prior 2 years
  • Pregnancy
  • In active surveillance or treatment for a current cancer diagnosis, or a recent cancer diagnosis requiring intervention within 5 years of the baseline assessment.
  • Unable to provide informed consent or lacks decision-making capacity
  • McGaw medical students, residents, and fellows, consistent with NU/FSM policy, to reduce coercion or undue influence. Employees may participate only under the safeguards described in the vulnerable populations section.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Screening
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Ingen indgriben: Cohort 1 (Medical Indication Group)

Adults 21 through 85 years of age with a clinical reason for chest CT, such as suspected lung pathology, abnormal chest imaging, or pulmonary symptoms requiring further evaluation. Cohort 1 participants undergo CT and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization.

Ingen indgriben: Cohort 2 (Guideline-Based Screening Group)

Adults 21 through 85 years of age who meet current USPSTF criteria for LDCT lung cancer screening. Cohort 2 participants undergo screening and follow-up as part of routine clinical care. Study activity is limited to secondary use of routine-care data under waiver of consent and HIPAA authorization.

Aktiv komparator: Cohort 3 (Asymptomatic Research LDCT Group)

Adults 21 through 85 years of age who are asymptomatic, do not have a clinical indication for chest CT, and do not meet current USPSTF lung cancer screening criteria. Cohort 3 participants will provide informed consent and HIPAA authorization before undergoing a single LDCT of the chest billed to the study.

A low-dose CT scan is an X-ray procedure where a high-speed computer is used to make multiple images of your chest area using the least amount of radiation possible without reducing the diagnostic quality of the exam.

Andre navne:
  • LDCT

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Primary Endpoint
Tidsramme: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Baseline prevalence of CT-detectable pulmonary abnormalities in Cohort 3.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Secondary Endpoint 1
Tidsramme: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Comparative baseline prevalence of pulmonary findings across Cohorts 1, 2, and 3.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 2
Tidsramme: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Prevalence and reported severity of coronary artery calcification in Cohort 3 and across cohorts, using the final radiology report categories, such as absent/present or none/mild/moderate/severe when available.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 3
Tidsramme: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Prevalence of bone-density-related abnormalities or vertebral compression fracture findings across all three cohorts using the final radiology report terminology.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 4
Tidsramme: For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.

Associations between baseline defined variables and LDCT-detectable findings.

For each patient, routine turnaround of non-critical findings as reported by the radiologist, or up to 1 week.
Secondary Endpoint 5
Tidsramme: 5 years

EHR-derived outcomes for up to 5 years after baseline/index LDCT, including clinically documented diagnoses, additional imaging, procedures, treatments, and mortality as available.

5 years

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Exploratory Endpoint 1
Tidsramme: 6 years

Subgroup analyses by age, sex, race/ethnicity, smoking status, and exposure categories.

6 years
Exploratory Endpoint 2
Tidsramme: 6 years

Exploratory prediction models if event counts support model development.

6 years
Exploratory Endpoint 3
Tidsramme: 6 years

Descriptive analyses of downstream clinical evaluation after baseline CT findings.

6 years

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Ankit J Bharat, MD, Northwestern Medicine Canning Thoracic Institute
  • Ledende efterforsker: Momen J Wahidi, MD, Northwestern Medicine Canning Thoracic Institute

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

16. september 2025

Primær færdiggørelse (Anslået)

16. september 2030

Studieafslutning (Anslået)

30. december 2031

Datoer for studieregistrering

Først indsendt

6. november 2026

Først indsendt, der opfyldte QC-kriterier

6. november 2026

Først opslået (Faktiske)

12. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

12. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Upon PI approval, de-identified, coded data may be shared with other investigators conducting IRB-approved projects to establish a longitudinal data repository to support future IRB-approved research on early detection, prevention, and management of pulmonary and cardiothoracic conditions. Genetic testing, biospecimen collection, quantitative imaging re-analysis, or other analyses are not currently planned. Recipients will be required to adhere to institutional data protection standards.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner